Genzyme Receives FDA Complete Response Letter for Clolar
By admin - Posted on October 8th, 2009
Tagged: Business
• Disease
• FDA
• Genzyme
• Health care
• Leukemia
• Pharmaceutical industry
• Pharmaceuticals
• Seniors
October 6, 2009 -- CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled clinical study be conducted for label expansion of Clolar in this indication.
In September, the FDA Oncologic Drugs Advisory Committee voted 9 to 3 that data from a randomized, controlled trial was necessary to establish the efficacy and safety of Clolar in the proposed adult AML indication. Genzyme had sought approval to expand the indication based on the findings from a single-arm trial in an adult AML population.
Genzyme intends to request a meeting with the FDA to discuss the optimal path forward, including what additional or ongoing studies may satisfy regulatory requirements.
Genzyme is conducting a randomized, placebo-controlled Phase 3 trial (CLASSIC I) comparing clofarabine in combination with cytarabine to cytarabine alone in relapsed and refractory adult AML patients 55 years old or older. The trial continues to exceed patient accrual expectations, and results are expected in 2011. Clofarabine, which is an approved agent in the treatment of relapsed or refractory pediatric acute lymphoblasic leukemia (ALL) after at least two prior regimens, is also being investigated in clinical trials by many of the leading AML experts and major cooperative leukemia investigation groups in the United States and Europe.
About Clolar
Clolar is currently approved for pediatric ALL patients who have relapsed or have refractory disease after at least two prior regimens. Clolar has Orphan Drug designation for AML and pediatric ALL, and seven years of market exclusivity in the United States for relapsed/refractory pediatric ALL. The FDA also granted six months of extended market exclusivity to Clolar under the Best Pharmaceuticals for Children Act. For more information about Clolar, please call 1-800-RX CLOLAR or visit www.CLOLAR.com.
Source: Genzyme Corporation
Scroll down for related articles:
Related articles
- 2009-10-08: Genzyme Receives FDA Complete Response Letter for Clolar
- 2009-05-26: Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
- 2009-10-08: Novartis completes shipment of US supply of Fluvirin® seasonal influenza vaccine
- 2009-06-05: Novartis Sees Encouraging Results from Tasigna in Leukemia Treatment
- 2009-06-01: GlaxoSmithKline: FDA Advisory Panel Makes Favorable Recommendation For ARZERRA (Ofatumumab)
- 2009-10-20: FDA approves GlaxoSmithKline’s Votrient for advanced renal cell cancer
- 2009-10-19: FDA approves Cervarix, GlaxoSmithKline’s cervical cancer vaccine
- 2009-10-08: Sanofi Pasteur Influenza A(H1N1) Vaccines Demonstrate Robust Immune Response After One Dose
- 2009-07-09: Alnylam joins GSK in donating intellectual property to patent pool for neglected tropical diseases
- 2009-07-09: Biogen Idec moves forward on MS drug
- 2009-07-02: AstraZeneca get European go-ahead for lung cancer drug
- 2009-06-22: Merck Responds to FDA on Leukotriene Inhibitors
